Abeona Therapeutics was founded in 2013 and is headquartered in Dallas, US

Report incorrect company information

Abeona Therapeutics has an office in Dallas

Dallas, US (HQ)

600 3333 Lee Pkwy

Report incorrect company information

Abeona Therapeutics's revenue was reported to be $889 k in FY, 2016 which is a **14.5% decrease** from the previous period.

USD | |
---|---|

## Revenue (Q3, 2017) | 219 k |

## Net income (Q3, 2017) | (5.3 m) |

## EBIT (Q3, 2017) | (5.4 m) |

## Market capitalization (5-Feb-2018) | 13.7 m |

## Cash (6-Mar-2018) | 56.5 m |

Abeona Therapeutics's current market capitalization is $13.7 m.

- Source: SEC Filings

Annual

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Revenue | 2 m | 925 k | 1 m | 889 k |

| (55%) | 12% | (15%) | |

## General and administrative expense | 13.3 m | |||

## R&D expense | 10.7 m |

Quarterly

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Revenue | 189 k | 208 k | 247 k | 236 k | 258 k | 285 k | 235 k | 214 k | 184 k | 186 k | 217 k | 219 k |

## General and administrative expense | 642 k | 733 k | 868 k | 795 k | 1.7 m | 4.7 m | 4.4 m | 3.7 m | 2.4 m | 3 m | 2.6 m | 2.2 m |

## R&D expense | 236 k | 72 k | 81 k | 73 k | 453 k | 1.6 m | 1.9 m | 3 m | 2.7 m | 2.2 m | 5.8 m | 3.3 m |

## Operating expense total | 885 k | 805 k | 950 k | 869 k | 2.3 m | 6.4 m | 6.4 m | 6.9 m | 5.4 m | 5.5 m | 8.7 m | 5.6 m |

- Source: SEC Filings

Annual

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Cash | 424 k | 11.5 m | 40.1 m | 69.1 m |

## Inventories | 77 k | 315 k | 155 k | |

## Current Assets | 575 k | 11.6 m | 40.6 m | 69.4 m |

## PP&E | 6 k | 4 k | 350 k | 721 k |

Quarterly

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 |
---|---|---|---|---|---|---|---|---|---|---|---|---|

## Cash | 899 k | 299 k | 55 k | 165 k | 7.9 m | 43.3 m | 37.4 m | 34.3 m | 31.2 m | 63.2 m | 58.3 m | 56.5 m |

## Inventories | 1.8 m | |||||||||||

## Current Assets | 1 m | 440 k | 203 k | 244 k | 8.2 m | 43.7 m | 37.8 m | 34.6 m | 31.9 m | 63.8 m | 59.3 m | 58.4 m |

## PP&E | 6 k | 6 k | 5 k | 4 k | 11 k | 87 k | 548 k | 639 k | 748 k | 748 k | 709 k | 730 k |

Annual

USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 |
---|---|---|---|---|

## Net Income | 4.4 m | (26.8 m) | (14.5 m) | (21.9 m) |

## Depreciation and Amortization | 3 k | 11 k | 551 k | 825 k |

## Inventories | 174 k | 77 k | (287 k) | 160 k |

## Accounts Payable | (1.2 m) | 33 k | (1.2 m) | 2.8 m |

Quarterly

USD | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 |
---|---|---|---|---|---|---|---|---|---|---|

## Net Income | (157 k) | (128 k) | (12.5 m) | (1.5 m) | (2 m) | (12.2 m) | (5.5 m) | (12.2 m) | (14.9 m) | (5.2 m) |

## Depreciation and Amortization | 1 k | 1 k | 118 k | 401 k | 174 k | 355 k | 577 k | 250 k | ||

## Accounts Payable | 1.1 m | 1.3 m | 1.6 m | 638 k | (1.1 m) | 1 m | 1.2 m | 1 m | 1.5 m | |

## Cash From Operating Activities | (7.5 m) | (5.6 m) | (9.6 m) |

USD | Y, 2017 |
---|---|

## Financial Leverage | 1.1 x |

Report incorrect company information